Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Attovia Therapeutics Q3 2026 Results: Net Loss of $22.3M, Loss Widens

Attovia Therapeutics is an emerging growth company focused on developing product candidates ATTO-1310, ATTO-2306, and ATTO-1091 for inflammatory and pruritic diseases. As of October 31, 2026, the company had 45,712,536 shares of common stock outstanding and continues to incur significant operating losses with no product revenue generated to date.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue0.00.4
Net income-22.3-13.8
EPS (diluted, $ a share)$-0.76$-3.44

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Source

10-Q filed with the SEC, NASDAQ: ATTO. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Attovia Therapeutics, Inc.: key numbers

Share price
$14.86Close, Nov 17
Market cap
$678M
Shares outstanding
45.65MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Attovia Therapeutics, Inc.

All →
4:11 PM ET 8-K
Clinical Trial Data

Attovia Therapeutics Clinical Trial Data

Attovia Therapeutics announced positive topline 12-week results from its Phase 1b study of ATTO-1310 in patients with chronic pruritus and high-itch atopic dermatitis. The data showed rapid and sustained itch relief with 82% of chronic pruritus patients achieving a clinically meaningful reduction in itch at Week 12, supporting the potential for quarterly maintenance dosing.

“The recently announced 12-week topline results from our ATTO-1310 Phase 1b trial exceeded our expectations, building on the compelling Week 4 findings and providing further evidence supporting our differentiated target product profile: rapid, deep, and durable itch relief, meaningful skin lesion improvements, the potential for quarterly dosing, and a favorable safety profile.”

Tao Fu, Founder and Chief Executive Officer of Attovia

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.